53077-21-7 Usage
Abbreviation
MNTM
Classification
Chemical compound, intermediate in pharmaceutical synthesis
Components
Morpholine ring
Thioxoethyl group
6-methoxy-2-naphthyl substituent
Therapeutic Properties
Potential anti-inflammatory effects
Potential anti-tumor activities
Research Interest
Subject of scientific research for drug development
Investigated for medical treatments
Applications
Used in chemical reactions
Employed in synthetic pathways for pharmaceutical compounds
Check Digit Verification of cas no
The CAS Registry Mumber 53077-21-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,0,7 and 7 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 53077-21:
(7*5)+(6*3)+(5*0)+(4*7)+(3*7)+(2*2)+(1*1)=107
107 % 10 = 7
So 53077-21-7 is a valid CAS Registry Number.
InChI:InChI=1/C17H19NO2S/c1-19-16-5-4-14-10-13(2-3-15(14)12-16)11-17(21)18-6-8-20-9-7-18/h2-5,10,12H,6-9,11H2,1H3
53077-21-7Relevant articles and documents
Phase-transfer catalyzed asymmetric arylacetate alkylation
Andrus, Merritt B.,Harper, Kaid C.,Christiansen, Michael A.,Binkley, Meisha A.
supporting information; experimental part, p. 4541 - 4544 (2009/12/03)
Phenethyl arylacetates are alkylated under phase-transfer conditions with cinchona catalysts with alkyl halides in high yield with excellent enantioselectivity (84-99% ee) following recrystallization. Cinchonidine (CD) derived catalyst gave the (R)-product and cinchonine (CN) catalyst produced the (S)-product. The phenethyl (PE) ester group is removed, using ammonium formate and catalytic Pd/C, to give alkylated carboxylic acid products in high selectivity. The utility of the approach is demonstrated by a direct synthesis of (S)-naproxen.
